Planet Labs PBC's high P/S ratio is backed by strong future revenue projections. Investors see a slim chance of revenue decrease, supporting the high ratio. Provided analysts' predictions are accurate, these robust revenue forecasts should sustain the share price.
The insider transactions at Planet Labs PBC indicate a bullish sentiment. Despite the shares currently trading below their purchase price, insiders have not sold any units over the last year, reflecting their confidence in the company's future prospects.
$Guidewire Software(GWRE.US)$— Shares slipped 2% in extended trading after the insurance software company reported that revenue for the fiscal first quarter would miss analysts' estimates. Guidewire is calling for revenue of $197 million to $202 million, while analysts polled by FactSet anticipated $212.5 million. $Smartsheet(SMAR.US)$— Smartsheet's stock popped 6% after the work management software company beat analyst estimates for second-quarter...
Planet Labs PBC股票討論區
$Smartsheet(SMAR.US)$ — Smartsheet's stock popped 6% after the work management software company beat analyst estimates for second-quarter...
$SpaceX(臨時代碼)(FT0002)$
$亞馬遜(AMZN.US)$
$Telesat(TSAT.US)$
$Planet Labs PBC(PL.US)$
$洛克希德馬丁(LMT.US)$
$Spire Global(SPIR.US)$
$特斯拉(TSLA.US)$
There are several companies involved in the development of satellite constellations. Here are some notable examples:
1. SpaceX (Starlink): SpaceX, led by Elon Musk, is developing the Starlink satellite constellation. It aims to provide global broadband internet coverage by deploying thousands...
In reaction to earnings/guidance:
• $Planet Labs PBC(PL.US)$ +11.3%, $Core & Main(CNM.US)$ +6.1%, $Regal Rexnord(RRX.US)$ +2% (reaffirms outlook), $甲骨文(ORCL.US)$ +1.6%
Other news:
• $Akero Therapeutics(AKRO.US)$ +93.2% (reports Phase 2b HARMONY Study)
• $Akouos(AKUS.US)$ +10.3% (FDA clears IND application to initiate a Phase 1/2 first in human pediatric clinical trial of AK-OTOF)
• $Catalyst Pharmaceuticals(CPRX.US)$ +7.7...
暫無評論